Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to […]
Generated record Q1 programmatic revenue, 34% year-over-year Adjusted EBITDA growth, and $37.7 million net cash from operating activities Reaffirming full […]
LOUISVILLE, Ky., May 20, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud […]